Fibrinogen - Grifols
Alternative Names: FIB-Grifols; Fibrinogen human - Grifols; Human plasma-derived fibrinogen concentrate - GrifolsLatest Information Update: 10 Dec 2021
Price :
$50 *
At a glance
- Originator Grifols
- Class Acute-phase proteins; Antihaemorrhagics; Blood coagulation factors; Coagulants
- Mechanism of Action Fibrinogen replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Afibrinogenaemia
Most Recent Events
- 24 Nov 2020 Grifols plans a phase III trial for Afibrinogenaemia (In Children, In Adolescents, In Adults, In Elderly) in December 2023 (NCT04636268)
- 11 Nov 2019 Grifols completes a phase I/II trial in Afibrinogenaemia in USA, India, Italy, Lebanon (NCT02281500)
- 29 Aug 2019 Fibrinogen is still in phase I/II trials for Afibrinogenaemia in India, USA (IV) (NCT02281500)